Despite a rocky Q1 start to 2025 with a 4.3% market drop, AbbVie managed to thrive amid economic unease and shifting investor ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

Citigroup has reiterated its neutral stance on AbbVie, nudging its price target down from $210 to $205, despite the company’s ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Neutral. Analyst ...

A congressional transaction is when any representative or senator either buys or sells an individual stock. Anyone working in Congress must file a Periodic Transaction Report to inform the public ...

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock traded at ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation.

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53% ...

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations ...

Shares of AbbVie Inc. ABBV slipped 1.21% to $196.07 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.64% to 5,650.38 and ...

The Janus kinase inhibitor was developed by scientists at AbbVie. Credit: © AbbVie Inc. All rights reserved. The US Food and Drug Administration (FDA) has granted ...